Initial results on Gardasil 9 chemical composition

Initial results on Gardasil 9 chemical composition

With the present analysis we come to the fourth vaccine tested by this method, aiming to verify the chemical-proteic composition of the analysed batches.

In this case we have focused on a vaccine that is not mandatory in Italy, the human papilloma virus one, but that has done much to discuss in the recent past because of the numerous reports of suspected adverse reactions filed over time. The anti-Hpv vaccines have always caused an intense debate, even outside Italy; hence our decision to focus our work on this product too.

Note: Gardasil 9 is an anti-Hpv vaccine that should contain 9 antigens as specified in the package insert, protecting from 9 different subtypes of the Hpv virus (subtype 6 -11 - 16 - 18 - 31 - 33 - 45 - 52 - 58). However, not all the indicated antigens have been detected, but 7 out of 9.


In this Gardasil 9 batch we have found, as for the previously analysed vaccines:

  • Chemical contaminations from the manufacturing process or cross-contaminations from different production lines
  • Chemical toxins

ANTIGENS: as mentioned above, Gardasil 9 should contain, as indicated in the package insert, 9 antigens against 9 different subtypes of the Hpv virus (subtype 6 -11 - 16 - 18 - 31 - 33 - 45 - 52 - 58 ).

Out of the above mentioned, we have not found:

  • L1 Type 11 Human Papillomavirus (one of the subtypes that are most commonly associated with cervical lesions)
  • L1 Type 58 Human Papillomavirus (one of the subtypes that is most frequently associated with cervical cancer)

These two subtypes have not been detected by the analysis method in use (unlike the remaining 7).


In this case too, therefore, we are confronted with a product that does NOT seem to contain what it should. Out of 9 antigens, only 7 have been found.
This opens up a major issue about the product compliance. An issue that is not up to us to resolve, and, as always, we put the question to those who are competent and responsible .

In addition, 338 signals of chemical contaminants were detected, of which 22% is known. This data is also in continuity with the previous results.
Among these signals 10 chemical toxins have been also identified, probably originating in the antigens’ manufacturing process or other processes at the vaccine production site.

In conclusion, even Gardasil 9 - as well as the hexavalent Hexyon and Infanrix hexa and the quadrivalent Priorix Tetra – as for the method we have commissioned, casts major doubts on both its effectiveness and on its safety.

These drugs, like any other pharmaceutical product, involve serious side-effects and can trigger different kinds of adverse reactions, even severe ones. Questioning the vaccine efficacy because one or more antigens are missing as compared with the manufacturer statement, this must be a well-known fact to those who decide to receive the vaccination (or otherwise that would constitute a fraudolent behavior on the part of those who sell and administer it); for this reason, it is very important to continue the scientific research on the vaccines content, taking into consideration that the main recipient is the paediatric population, and the subjects who receive the vaccines do not suffer from any manifest pathology, and the institutions themselves are indicating such a preventive prophylaxis, using these products, as necessary. The istitutions are therefore directly involved in the assessment of the product safety profile and its compliance.


Download: CORVELVA-Study-on-the-chemical-composition-profile-of-Gardasil9.pdf


Translated by team CLiVa - www.clivatoscana.com